1[1]Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002 ;41(7) :471 - 83.
2[2]Gribble FM, Reimann F. Differential selectivity of insulin secretagogues:mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003 Mar- Apr; 17(2 Suppl):11-5.
3[3]Standl E, Fuchtenbusch M. The role of oral antidiabetic agents: why and when to use an early - phase insulin secretion agent in Type Ⅱ diabetes mellitus. Diabetologia 2003 Mar; 46Suppl 1: M30 - 6. Epub 2002 Dec 18.
4[4]Owens DR, Cozma LS, Luzio SD. Early - phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabetes Nutr Metab 2002 Dec; 15(6 Suppl): 19 - 27.
5[5]Moses R. Repaglinide in combination therapy. Diabetes Nutr Metab 2002 Dec; 15(6 SUppl) :33 - 8.
6[6]Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001 ;61(11): 1625 - 60.
7[7]Hasslacher C; Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003 Mar;26(3) :886 - 91.
8[8]Owens D. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes. J Assoc Physicians India 2001 Jan 25;49:54 - 61.
9[9]Ambavane V, Patil R, Ainapure SS. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. J Postgrad Med 2002 Jul- Sep;48(3) :246 - 8.
10[10]Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naive Type 2diabetes:a placebo- controlled, multicentre study. Qual Life Res 2003 Jun;12(4):413-425.
6Kikuo S, James L, Young A, et al. Netformin inhibits proinglammatory responses and nuclear factor k-B in human vascular wall cells[J]. Arterioscler Thromb Vasc Biol, 2006, 26 (3) : 611 - 613.
7Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetes patients. Diabetes 1999,48 : 90 - 105.
8Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events:A met - regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999,22(2):223 - 240.
9Rudovich MG, Leyck Dieken H, Rochilita A. F. H. Preiffer Exp Clin Endocrinol Diabetes. 2004,112:395 - 400.
10MR Rizzo, M Barbieri, R Grella, N Possariello, M Barune:G Paolisso. Diabetes Metal 2004,30 : 81 - 89.
